Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials
Brigham and Women's Hospital · Thrombolysis in Myocardial Infarction Study Group · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
703
total citations
- FWCI
- 58.81
- Percentile
- 100%
- References
- 46
Citations per year
Authors
17- JLJessica L. MegaCorresponding
Brigham and Women's Hospital, Thrombolysis in Myocardial Infarction Study Group, Harvard University
- NONathan O. StitzielCorresponding
Washington University in St. Louis
- JGJ. G. Smith
Massachusetts General Hospital, Skåne University Hospital, Broad Institute, Harvard University, Lund University
- DIDaniel I. Chasman
Brigham and Women's Hospital
- MJMark J. Caulfield
William Harvey Research Institute, Queen Mary University of London
Topics & keywords
Topics
Keywords
- Medicine
- Internal medicine
- Statin
- Hazard ratio
- Framingham Risk Score
- Relative risk
- Disease
- Cardiology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.